DOCSLIB.ORG

Expression of a Homodimeric Type I Cytokine Receptor Is Required for JAK2V617F-Mediated Transformation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Expression of a Homodimeric Type I Cytokine Receptor Is Required for JAK2V617F-Mediated Transformation Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation Xiaohui Lu*†, Ross Levine†‡, Wei Tong*, Gerlinde Wernig‡, Yana Pikman‡, Sara Zarnegar*, D. Gary Gilliland‡§¶, and Harvey Lodish*ʈ *Whitehead Institute for Biomedical Research and the Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142; and ‡Division of Hematology, Department of Medicine, and §Howard Hughes Medical Institute, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115 Contributed by Harvey Lodish, November 9, 2005 A recurrent somatic activating mutation in the nonreceptor ty- says revealed that JAK2V617F transforms certain lines of hema- rosine kinase JAK2 (JAK2V617F) occurs in the majority of patients topoietic cells that express the erythropoietin receptor (EpoR) to with the myeloproliferative disorders polycythemia vera, essential growth factor independence and induces constitutive phosphory- thrombocythemia, myelofibrosis with myeloid metaplasia, and, lation of the STAT5 transcription factor (9, 11). The specificity of less commonly, chronic myelomonocytic leukemia. We do not the JAK2V617F mutation in clonal disorders of the myeloid, but not understand the basis for the specificity of the JAK2V617F mutation lymphoid, lineage and the pleiotropic phenotype of JAK2V617F- in clonal disorders of the myeloid, but not lymphoid, lineage, nor associated myeloproliferative disorders are not fully understood. has the basis for the pleiotropic phenotype of JAK2V617F-associ- Here, we show that JAK2V617F functions differently from ated myeloproliferative disorders been delineated. However, the constitutively activated kinases, such as TEL-JAK2. In IL-3- presence of the identical mutation in patients with related, but dependent hematopoietic cell lines, the ability of JAK2V617F to clinicopathologically distinct, myeloid disorders suggests that in- induce cytokine-independent activation of the JAK2 and STAT5 teractions between the JAK2V617F kinase and other signaling pathways and transformation to cytokine independence requires molecules may influence the phenotype of hematopoietic progen- the coexpression of homodimeric Type I cytokine receptors, itors expressing JAK2V617F. Here, we show that coexpression of such as EpoR, thrombopoietin receptor (TpoR), or granulocyte the JAK2V617F mutant kinase with a homodimeric Type I cytokine colony-stimulating-factor receptor (GCSFR). Further, a mutant receptor, the erythropoietin receptor (EpoR), the thrombopoietin EpoR that fails to bind JAK2 also fails to support JAK2V617F- receptor, or the granulocyte colony-stimulating-factor receptor, is mediated transformation and constitutive STAT5 activation. An necessary for transformation of hematopoietic cells to growth- EpoR mutant that lacks cytosolic tyrosines and is deficient in factor independence and for hormone-independent activation of Epo-induced STAT5 activation supports cytokine-independent JAK-STAT signaling. Furthermore, EpoR mutations that impair activation of JAK2V617F but is defective in supporting erythropoietin-mediated JAK2 or STAT5 activation also impair JAK2V617F-mediated STAT5 activation and cytokine- transformation mediated by the JAK2V617F kinase, indicating that independent growth. Our results suggest that, unlike other JAK2V617F requires a cytokine receptor scaffold for its transform- constitutively activating kinase mutants previously identified, ing and signaling activities. Our results reveal the molecular basis JAK2V617F depends on cognate cytokine receptors for both its for the prevalence of JAK2V617F in diseases of myeloid lineage activation and the activation of downstream signal-transduction cells that express these Type I cytokine receptors but not in proteins. This finding provides mechanistic insights into the lymphoid lineage cells that do not. prevalence of JAK2V617F in myeloproliferative diseases like essential thrombocythemia, polycythemia vera, and myeloid erythropoietin receptor ͉ myeloproliferative diseases ͉ STAT5 activation metaplasia and reveals the origins of dysregulation in JAK2V617F-mediated cell growth. onstitutive activation of tyrosine kinases by chromosomal Ctranslocation (1), interstitial deletion (2), internal tandem Materials and Methods duplication (3), or amino acid substitution (4) are frequent Expression Vectors. The murine JAK2 cDNA was cloned into the pathogenetic events in hematopoietic malignancies. These con- retroviral vectors MSCV-Neo and MSCV-GFP. The JAK2V617F stitutively activated kinases are disengaged from normal regu- mutation was generated by using site-directed mutagenesis latory mechanisms and activate signal-transduction pathways, (QuikChange-XL, Stratagene) and confirmed by full-length including the STAT, RAS͞MAPK, and PI3K͞AKT pathways DNA sequencing. that confer proliferative and survival advantage to hematopoi- etic progenitors. For example, TEL-JAK2 is a chimeric tyrosine Cell Culture. The 293T cells were grown in Dulbecco’s modified kinase that is expressed in hematopoietic malignancies as a Eagle’s medium with 10% FCS. Transient cotransfection of consequence of the t (9, 12)(p24;p13) translocation (5, 6). JAK2 293T cells and generation of retroviral supernatant were is normally tightly associated with the cytosolic domain of a performed as described in ref. 14. Parental Ba͞F3 cells, Ba͞F3 cytokine receptor and, after cytokine binding to the cognate receptor, becomes activated by transphosphorylation of a ty- rosine residue in the activation loop. In contrast, TEL-JAK2 is Conflict of interest statement: No conflicts declared. localized to the cytosol and activates STAT5 without a require- Abbreviations: Epo, erythropoietin; EpoR, erythropoietin receptor; GCSFR, granulocyte colony-stimulating-factor receptor; PrlR, prolactin receptor; TpoR, thrombopoietin ment for cytokine stimulation or binding to a cytokine receptor receptor. (7). Indeed, the TEL-JAK2 fusion lacks the conserved JH3 to †X.L. and R.L. contributed equally to this work. JH7 domains that are required for JAK2 association with ¶To whom correspondence may be addressed at: Brigham and Women’s Hospital, 1 cytokine receptors (8). Blackfan Circle, Room 5120, Harvard Medical School, Boston, MA 02115. E-mail: ggilliland@ We and others recently reported an association between a rics.bwh.harvard.edu. somatic point mutation of the JAK2 tyrosine kinase (JAK2V617F) ʈTo whom correspondence may be addressed at: 9 Cambridge Center, Cambridge, and the myeloproliferative diseases polycythemia vera, essential MA 02142. E-mail: [email protected]. thrombocythemia, and myeloid metaplasia (9–13). Functional as- © 2005 by The National Academy of Sciences of the USA 18962–18967 ͉ PNAS ͉ December 27, 2005 ͉ vol. 102 ͉ no. 52 www.pnas.org͞cgi͞doi͞10.1073͞pnas.0509714102 Downloaded by guest on October 2, 2021 Fig. 1. A homodimeric Type I cytokine receptor is required for JAK2V617F-mediated transformation of Ba͞F3 cells. (a) Parental Ba͞F3 cells stably expressing wild-type JAK2 (Ba͞F3 WT-JAK2, open circles), JAK2V617F (Ba͞F3 JAK2V617F, open triangles), or TEL-JAK2 fusion cDNA (Ba͞F3 TEL-JAK2, open squares) were cultured in RPMI medium 1640͞10% FCS in the absence of IL-3, demonstrating cytokine-independent growth for Ba͞F3 cells expressing TEL-JAK2 but not wild-type JAK2 or JAK2V617F. Each data point represents the average of a duplicate, if not specified otherwise. (b)Ba͞F3 EpoR cells stably expressing wild-type JAK2 (Ba͞F3 EpoR WT-JAK2, filled circles), JAK2V617F (Ba͞F3 EpoR JAK2V617F, filled triangles), or TEL-JAK2 fusion cDNA (Ba͞F3 EpoR TEL-JAK2, filled squares) were cultured in RPMI medium 1640͞10% FCS in the absence of IL-3, demonstrating cytokine-independent growth for Ba͞F3 EpoR cells expressing either TEL-JAK2 or JAK2V617F but not wild-type JAK2. (c)Ba͞F3 cells stably coexpressing TpoR and JAK2V617F (Ba͞F3 TpoR JAK2V617F, filled triangles), JAK2V617F alone (Ba͞F3 JAK2V617F, open triangles), wild-type JAK2 alone (Ba͞F3 WT-JAK2, open circles), or TpoR together with wild-type JAK2 (Ba͞F3 TpoR WT-JAK2, filled circles) were cultured in RPMI medium 1640͞10% FCS in the absence of IL-3, demonstrating IL-3-independent growth for Ba͞F3 cells stably coexpressing TpoR and JAK2V617F but not cells expressing wild-type JAK2 or JAK2V617F alone. (d)Ba͞F3 cells stably coexpressing GCSFR and JAK2V617F (Ba͞F3 GCSFR JAK2V617F, filled triangles), expressing only JAK2V617F (Ba͞F3 JAK2V617F, open triangles), only wild-type JAK2 (Ba͞F3 WT-JAK2, open circles), or GCSFR together with wild-type JAK2 (Ba͞F3 GCSFR WT-JAK2, filled circles) were cultured in RPMI medium 1640͞10% FCS in the absence of IL-3, demonstrating IL-3-independent growth only for Ba͞F3 cells stably coexpressing JAK2V617F and GCSFR. cells expressing the murine EpoR (BaF3 EpoR) (15), and Results Ba͞F3 cells expressing murine TpoR (Ba͞F3 TpoR) (14) were Expression of a Homodimeric Type I Cytokine Receptor Is Required for grown in RPMI medium 1640 containing 10% FCS and 10% JAK2V617F-Mediated Transformation of Ba͞F3 Cells. We demon- WEHI-3B cell supernatant as a source of IL-3 (WEHI media). strated that expression of TEL-JAK2 transforms the murine These cells were transduced with retroviral supernatant con- IL-3-dependent hematopoietic cell line Ba͞F3 to factor- taining either the MSCV-JAK2-Neo or MSCV-JAK2V617F- independent growth (7) (Fig. 1a). These properties are similar to Neo vectors, respectively, and then selected in G418 (1 mg͞ those reported by our group and others for a number of mutant ml). Ba͞F3 cells expressing human GCSFR
Load more

Recommended publications
  • Induction of Erythropoietin Increases the Cell Proliferation Rate in a Hypoxia‑Inducible Factor‑1‑Dependent and ‑Independent Manner in Renal Cell Carcinoma Cell Lines
    ONCOLOGY LETTERS 5: 1765-1770, 2013 Induction of erythropoietin increases the cell proliferation rate in a hypoxia‑inducible factor‑1‑dependent and ‑independent manner in renal cell carcinoma cell lines YUTAKA FUJISUE1, TAKATOSHI NAKAGAWA2, KIYOSHI TAKAHARA1, TERUO INAMOTO1, SATOSHI KIYAMA1, HARUHITO AZUMA1 and MICHIO ASAHI2 Departments of 1Urology and 2Pharmacology, Faculty of Medicine, Osaka Medical College, Takatsuki, Osaka 569-8686, Japan Received November 28, 2012; Accepted February 25, 2013 DOI: 10.3892/ol.2013.1283 Abstract. Erythropoietin (Epo) is a potent inducer of erythro- Introduction poiesis that is mainly produced in the kidney. Epo is expressed not only in the normal kidney, but also in renal cell carcinomas Erythropoietin (Epo) is a 30-kDa glycoprotein that functions (RCCs). The aim of the present study was to gain insights as an important cytokine in erythrocytes. Epo is usually into the roles of Epo and its receptor (EpoR) in RCC cells. produced by stromal cells of the adult kidney cortex or fetal The study used two RCC cell lines, Caki-1 and SKRC44, in liver and then released into the blood, with its production which Epo and EpoR are known to be highly expressed. The initially induced by hypoxia or hypotension (1-5). In the bone proliferation rate and expression level of hypoxia-inducible marrow, Epo binds to the erythropoietin receptor (EpoR) factor-1α (HIF-1α) were measured prior to and following expressed in erythroid progenitor cells or undifferentiated Epo treatment and under normoxic and hypoxic conditions. erythroblasts, which induces signal transduction mechanisms To examine whether HIF-1α or Epo were involved in cellular that protect the undifferentiated erythrocytes from apoptosis proliferation during hypoxia, these proteins were knocked and promote their proliferation and differentiation.
    [Show full text]
  • Targeted Erythropoietin Selectively Stimulates Red Blood Cell Expansion in Vivo
    Targeted erythropoietin selectively stimulates red blood cell expansion in vivo Devin R. Burrilla, Andyna Verneta, James J. Collinsa,b,c,d, Pamela A. Silvera,e,1, and Jeffrey C. Waya aWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115; bSynthetic Biology Center, Massachusetts Institute of Technology, Cambridge, MA 02139; cInstitute for Medical Engineering & Science, Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139; dBroad Institute of MIT and Harvard, Cambridge, MA 02139; and eDepartment of Systems Biology, Harvard Medical School, Boston, MA 02115 Edited by Ronald A. DePinho, University of Texas MD Anderson Cancer Center, Houston, TX, and approved March 30, 2016 (received for review December 23, 2015) The design of cell-targeted protein therapeutics can be informed peptide linker that permits simultaneous binding of both elements by natural protein–protein interactions that use cooperative phys- to the same cell surface. The targeting element anchors the mu- ical contacts to achieve cell type specificity. Here we applied this tated activity element to the desired cell surface (Fig. 1A, Middle), approach in vivo to the anemia drug erythropoietin (EPO), to direct thereby creating a high local concentration and driving receptor its activity to EPO receptors (EPO-Rs) on red blood cell (RBC) pre- binding despite the mutation (Fig. 1A, Bottom). Off-target sig- cursors and prevent interaction with EPO-Rs on nonerythroid cells, naling should be minimal (Fig. 1B) and should decrease in pro- such as platelets. Our engineered EPO molecule was mutated to portion to the mutation strength. weaken its affinity for EPO-R, but its avidity for RBC precursors Here we tested the chimeric activator strategy in vivo using was rescued via tethering to an antibody fragment that specifi- erythropoietin (EPO) as the drug to be targeted.
    [Show full text]
  • Immunohistochemical Expression of Erythropoietin in Invasive Breast Carcinoma with Metastasis to Lymph Nodes
    Review and Research on Cancer Treatment Volume 4, Issue 1 (2018) ISSN 2544-2147 Immunohistochemical expression of erythropoietin in invasive breast carcinoma with metastasis to lymph nodes Maksimiuk M.* Students' Scientific Organization at the Medical University of Warsaw, Oczki 1a, 02-007 Warsaw Sobiborowicz A. Students' Scientific Organization at the Medical University of Warsaw, Oczki 1a, 02-007 Warsaw Sobieraj M. Students' Scientific Organization at the Medical University of Warsaw, Oczki 1a, 02-007 Warsaw Liszcz A. Students' Scientific Organization at the Medical University of Warsaw, Oczki 1a, 02-007 Warsaw Sobol M. Department of Biophysics and Human Physiology, Medical University of Warsaw, Chałubińskiego 5, 02-004 Warsaw Patera J. Department of Pathomorphology, Military Institute of Health Services, Warsaw, Poland Badowska-Kozakiewicz A.M. Department of Biophysics and Human Physiology, Medical University of Warsaw, Chałubińskiego 5, 02-004 Warsaw *corresponding author: Marta Maksimiuk, Department of Biophysics and Human Physiology, Medical University of Warsaw, Chałubińskiego 5, 02-004 Warsaw, [email protected], tel: 691 – 230 – 268 Abstract: Introduction: Tumor characteristics, such as size, lymph node status, histological type of the neoplasm and its grade, are well known prognostic factors in breast cancer. The ongoing search for new prognostic factors include Bcl2, Bax, Cox-2 or HIF1- alpha, which plays a key role in phenomenon of tumor hypoxia and might induce transcription of the EPO gene. Erythropoietin may influence lymph node metastasis or stimulate tumor progression, thus it seemed interesting to determine its expression in invasive breast cancers with lymph node metastases presenting different basic immunohistochemical profiles (ER, PR, HER2). Aim: To evaluate the relationship between histological grade, tumor size, lymph node status, expression of ER, PR, HER2 and immunohistochemical expression of erythropoietin in invasive breast cancer with metastasis to lymph nodes.
    [Show full text]
  • The Thrombopoietin Receptor : Revisiting the Master Regulator of Platelet Production
    This is a repository copy of The thrombopoietin receptor : revisiting the master regulator of platelet production. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/175234/ Version: Published Version Article: Hitchcock, Ian S orcid.org/0000-0001-7170-6703, Hafer, Maximillian, Sangkhae, Veena et al. (1 more author) (2021) The thrombopoietin receptor : revisiting the master regulator of platelet production. Platelets. pp. 1-9. ISSN 0953-7104 https://doi.org/10.1080/09537104.2021.1925102 Reuse This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here: https://creativecommons.org/licenses/ Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Platelets ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/iplt20 The thrombopoietin receptor: revisiting the master regulator of platelet production Ian S. Hitchcock, Maximillian Hafer, Veena Sangkhae & Julie A. Tucker To cite this article: Ian S. Hitchcock, Maximillian Hafer, Veena Sangkhae & Julie A. Tucker (2021): The thrombopoietin receptor: revisiting the master regulator of platelet production, Platelets, DOI: 10.1080/09537104.2021.1925102 To link to this article: https://doi.org/10.1080/09537104.2021.1925102 © 2021 The Author(s).
    [Show full text]
  • As a Key Regulator of Erythropoiesis, Bone Remodeling and Endothelial
    cells Review Erythropoietin (EPO) as a Key Regulator of Erythropoiesis, Bone Remodeling and Endothelial Transdifferentiation of Multipotent Mesenchymal Stem Cells (MSCs): Implications in Regenerative Medicine Asterios S. Tsiftsoglou Laboratory of Pharmacology, Department of Pharmaceutical Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece; [email protected] Abstract: Human erythropoietin (EPO) is an N-linked glycoprotein consisting of 166 aa that is pro- duced in the kidney during the adult life and acts both as a peptide hormone and hematopoietic growth factor (HGF), stimulating bone marrow erythropoiesis. EPO production is activated by hypoxia and is regulated via an oxygen-sensitive feedback loop. EPO acts via its homodimeric erythropoietin receptor (EPO-R) that increases cell survival and drives the terminal erythroid mat- uration of progenitors BFU-Es and CFU-Es to billions of mature RBCs. This pathway involves the activation of multiple erythroid transcription factors, such as GATA1, FOG1, TAL-1, EKLF and BCL11A, and leads to the overexpression of genes encoding enzymes involved in heme biosynthesis Citation: Tsiftsoglou, A.S. and the production of hemoglobin. The detection of a heterodimeric complex of EPO-R (consist- Erythropoietin (EPO) as a Key ing of one EPO-R chain and the CSF2RB β-chain, CD131) in several tissues (brain, heart, skeletal Regulator of Erythropoiesis, Bone muscle) explains the EPO pleotropic action as a protection factor for several cells, including the Remodeling and Endothelial multipotent MSCs as well as cells modulating the innate and adaptive immunity arms. EPO induces Transdifferentiation of Multipotent the osteogenic and endothelial transdifferentiation of the multipotent MSCs via the activation of Mesenchymal Stem Cells (MSCs): EPO-R signaling pathways, leading to bone remodeling, induction of angiogenesis and secretion Implications in Regenerative of a large number of trophic factors (secretome).
    [Show full text]
  • Correlation with Vasculogenic Mimicry and Poor Prognosis
    Int J Clin Exp Pathol 2015;8(4):4033-4043 www.ijcep.com /ISSN:1936-2625/IJCEP0006586 Original Article Erythropoietin and erythropoietin receptor in hepatocellular carcinoma: correlation with vasculogenic mimicry and poor prognosis Zhihong Yang1,2*, Baocun Sun1,2,3*, Xiulan Zhao1,2*, Bing Shao1, Jindan An1, Qiang Gu1,2, Yong Wang1, Xueyi Dong1, Yanhui Zhang1,3, Zhiqiang Qiu1,3 1Department of Pathology, Tianjin Medical University, Tianjin 300070, China; 2Department of Pathology, General Hospital of Tianjin Medical University, Tianjin 300052, China; 3Department of Pathology, Cancer Hospital of Tianjin Medical University, Tianjin 300060, China. *Equal contributors. Received February 1, 2015; Accepted March 30, 2015; Epub April 1, 2015; Published April 15, 2015 Abstract: To evaluate erythropoietin (Epo) and erythropoietin receptor (EpoR) expression, its relationship with vas- culogenic mimicry (VM) and its prognostic value in human hepatocellular carcinoma (HCC), we examined Epo/EpoR expression and VM formation using immunohistochemistry and CD31/PAS (periodic acid-Schiff) double staining on 92 HCC specimens. The correlation between Epo/EpoR expression and VM formation was analyzed using two-tailed Chi-square test and Spearman correlation analysis. Survival curves were generated using Kaplan-Meier method. Multivariate analysis was performed using Cox regression model to assess the prognostic values. Results showed positive correlation between Epo/EpoR expression and VM formation (P < 0.05). Patients with Epo or EpoR expres- sion exhibited poorer overall survival (OS) than Epo-negative or EpoR-negative patients (P < 0.05). Epo-positive/VM- positive and EpoR-positive/VM-positive patients had the worst OS (P < 0.05). In multivariate survival analysis, age, Epo and EpoR were independent prognostic factors related to OS.
    [Show full text]
  • Investigation of the Protective Effect of Erythropoietin on Spinal Cord Injury in Rats
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 2: 837-841, 2011 Investigation of the protective effect of erythropoietin on spinal cord injury in rats ZHENGHUA HONG, HUAXING HONG, HAIXIAO CHEN, ZHANGFU WANG and DUN HONG Department of Orthopedics, Taizhou Hospital of Zhejiang Province, Taizhou 317000, P.R. China Received May 2, 2011; Accepted June 6, 2011 DOI: 10.3892/etm.2011.285 Abstract. Erythropoietin (EPO) is a promising therapeutic cell apoptosis occurs at the lesion site, affecting both neurons agent used in a variety of spinal cord injuries. Therefore, iden- and astrocytes (1,2) It has long been believed that the central tifying the specific molecular pathway mediating the neuronal nervous system (CNS) is incapable of regenerating itself after protective effect of EPO after spinal cord injury (SCI) is of injury and during the repair process after SCI. Thus, an ideal great value to the patients concerned. Platelet-derived growth treatment would be one administered systemically but without factor (PDGF)-B is an important factor in the recovery of significant side effects. Erythropoietin( EPO), a potent inhibitor neurological function. We explored changes in the expression of apoptosis and a promising therapeutic agent, has been used of PDGF-B in spinal cord injury rats after receiving EPO treat- in a variety of neurological insults, including traumatic brain ment. We used a weight-drop contusion SCI model, and EPO injury, brain stroke and spinal cord injury (3,4). Therefore, treatment group rats received single doses ofEPO (1,000 U/ identifying the specific molecular pathway mediating the EPO kg i.p.) immediately after the operation. Seven days after the neuronal protective effects of EPO after SCI is of great value operation, the results revealed a more rapid recovery as noted to the patients concerned.
    [Show full text]
  • Erythropoietin and Cancer: the Unintended Consequences of Anemia Correction
    REVIEW ARTICLE published: 11 November 2014 doi: 10.3389/fimmu.2014.00563 Erythropoietin and cancer: the unintended consequences of anemia correction Nataša Debeljak 1*, Peter Solár 2 and Arthur J. Sytkowski 3 1 Faculty of Medicine, Institute of Biochemistry, University of Ljubljana, Ljubljana, Slovenia 2 Department of Cell and Molecular Biology, Institute of Biology and Ecology, Faculty of Sciences, Pavol Jozef Šafárik University, Košice, Slovakia 3 Oncology Therapeutic Area, Quintiles Transnational, Arlington, MA, USA Edited by: Until 1990, erythropoietin (EPO) was considered to have a single biological purpose and Pietro Ghezzi, Brighton and Sussex action, the stimulation of red blood cell growth and differentiation. Slowly, scientific and Medical School, UK medical opinion evolved, beginning with the discovery of an effect on endothelial cell Reviewed by: Ralf Schindler, Charité, Germany growth in vitro and the identification of EPO receptors (EPORs) on neuronal cells. We Domenico Ribatti, University of Bari now know that EPO is a pleiotropic growth factor that exhibits an anti-apoptotic action on Medical School, Italy numerous cells and tissues, including malignant ones. In this article, we present a short Chris Thiemermann, Queen Mary discussion of EPO, receptors involved in EPO signal transduction, and their action on non- University of London, UK hematopoietic cells. This is followed by a more detailed presentation of both pre-clinical *Correspondence: Nataša Debeljak, Faculty of Medicine, and clinical data that demonstrate EPO’s action on cancer cells, as well as tumor angio- Institute of Biochemistry, University genesis and lymphangiogenesis. Clinical trials with reported adverse effects of chronic of Ljubljana, Vrazov trg 2, SI-1000 erythropoiesis-stimulating agents (ESAs) treatment as well as clinical studies exploring Ljubljana, Slovenia the prognostic significance of EPO and EPOR expression in cancer patients are reviewed.
    [Show full text]
  • Red Blood Cell Microrheological Effects of Some Antitumor Chemotherapy Drugs: in Vitro Study
    Journal of Cellular Biotechnology 1 (2015/2016) 151–158 151 DOI 10.3233/JCB-15015 IOS Press Red blood cell microrheological effects of some antitumor chemotherapy drugs: In vitro study A.V. Muravyova,∗, I.A. Tikhomirovaa, N.V. Kislovb and A.S. Petrochenkoa aState Pedagogical University, Yaroslavl, Russia bRegional Oncological Hospital, Yaroslavl, Russia Abstract. In consequence of limitation of capillary dilatation reserve the role of erythrocyte membrane elasticity and their microrheological properties is very important for the tissue perfusion. The drugs that enter blood flow could be as signaling molecules and their action can lead to alteration of red blood cell aggregation and whole cell deformability. Therefore the subject of this study was to estimate the effect of some antitumor chemotherapy drugs on red blood cell aggregation (RBCA) and deformability (RBCD). It was found that an exposure of red blood cells (RBCs) to cisplatin and epoetin alfa led to significant positive changes in the RBC microrheological properties. It was shown that cisplatin could activate tyrosine protein kinase (TPK). Preincubation of RBCs with the inhibitor of EGF-R and Src kinase lavendustin A was accompanied by a significant decrease of the cisplatin effect. It was found RBC aggregation rise after cell incubation with 5-fluorouracil. This effect was removed with Ca2+ chelation with EGTA and also with pentoxifylline. The drug for the targeted antitumor therapy sunitinib raised RBCA markedly. Whereas RBC deformability index was altered only slightly. The combination of two chemicals: sunitinib and cisplatin led to an elimination of proaggregative effect of sunitinib. Examination of the effects of some antitumor drugs on red blood cell microrheological properties has enabled us to suggest that the observed changes in red cell aggregation and deformability may be partly related to the effects of tyrosine protein kinase activation.
    [Show full text]
  • Inactivation of Erythropoietin Receptor Function by Point Mutations in a Region Having Homology with Other Cytokine Receptors OSAMU MIURA,'T JOHN L
    MOLECULAR AND CELLULAR BIOLOGY, Mar. 1993, p. 1788-1795 Vol. 13, No. 3 0270-7306/93/031788-08$02.00/0 Copyright © 1993, American Society for Microbiology Inactivation of Erythropoietin Receptor Function by Point Mutations in a Region Having Homology with Other Cytokine Receptors OSAMU MIURA,'t JOHN L. CLEVELAND,' AND JAMES N. IHLEl,2* Department ofBiochemistry, St. Jude Children's Research Hospital, Memphis, Tennessee 31051,1 and Department ofBiochemistry, University of Tennessee, Memphis, Tennessee 3816332 Received 13 July 1992/Returned for modification 12 August 1992/Accepted 21 December 1992 The cytoplasmic domain of the erythropoietin receptor (EpoR) contains a region, proximal to the transmembrane domain, that is essential for function and has homology with other members of the cytokine receptor family. To explore the functional significance of this region and to identify critical residues, we introduced several amino acid substitutions and examined their effects on erythropoietin-induced mitogenesis, tyrosine phosphorylation, and expression of immediate-early (c-fos, c-myc, and egr-1) and early (ornithine decarboxylase and T-cell receptor 'y) genes in interleukin-3-dependent cell lines. Amino acid substitution of W-282, which is strictly conserved at the middle portion of the homology region, completely abolished all the functions of the EpoR. Point mutation at L-306 or E-307, both of which are in a conserved LEVL motif, drastically impaired the function of the receptor in all assays. Other point mutations, introduced into less conserved amino acid residues, did not significantly impair the function of the receptor. These results demonstrate that conserved amino acid residues in this domain of the EpoR are required for mitogenesis, stimulation of tyrosine phosphorylation, and induction of immediate-early and early genes.
    [Show full text]
  • Erythropoietin Promotes Breast Tumorigenesis Through Tumor-Initiating Cell Self-Renewal Bing Zhou,1 Jeffrey S
    Downloaded on January 20, 2014. The Journal of Clinical Investigation. More information at www.jci.org/articles/view/69804 Research article Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal Bing Zhou,1 Jeffrey S. Damrauer,1 Sean T. Bailey,1 Tanja Hadzic,1 Youngtae Jeong,2 Kelly Clark,1 Cheng Fan,1 Laura Murphy,1 Cleo Y. Lee,2 Melissa A. Troester,3 C. Ryan Miller,4 Jian Jin,1,5 David Darr,1 Charles M. Perou,1 Ross L. Levine,6 Maximilian Diehn,2 and William Y. Kim1 1Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 2Department of Radiation Oncology, Cancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California, USA. 3Department of Epidemiology and 4Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 5Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA. 6Human Oncology and Pathogenesis Program, Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. Erythropoietin (EPO) is a hormone that induces red blood cell production. In its recombinant form, EPO is the one of most prescribed drugs to treat anemia, including that arising in cancer patients. In randomized trials, EPO administration to cancer patients has been associated with decreased survival. Here, we investi- gated the impact of EPO modulation on tumorigenesis. Using genetically engineered mouse models of breast cancer, we found that EPO promoted tumorigenesis by activating JAK/STAT signaling in breast tumor-initi- ating cells (TICs) and promoted TIC self renewal.
    [Show full text]
  • Erythropoietin and Growth Factors Exhibit Differential Angiogenic Potential in Mouse Heart
    in vivo 22 : 587-592 (2008) Erythropoietin and Growth Factors Exhibit Differential Angiogenic Potential in Mouse Heart OLGA PAGONOPOULOU 1, ANNA EFTHIMIADOU 1, MARIA LAMBROPOULOU 2, NIKOS PAPADOPOULOS 2 and NIKOS K. NIKOLETTOS 1 Departments of 1Physiology and 2Histology – Embryology, Democritus University of Thrace, Medical School, Alexandroupolis, 68100, Greece Abstract. Background: The possible angiogenic effect of functions of EPO, angiogenesis, the process through which recombinant human erythropoietin (rHuEpo) and several new blood vessels arise from preexisting ones, has been possibly angiogenic cytokines such as basic fibroblast growth indicated (5). The potential role of EPO in angiogenesis may factor (bFGF), acidic fibroblast growth factor (aFGF) and be considered as a subset of its possible function in improving vascular endothelial growth factor (VEGF) was investigated overall tissue oxygenation and its antiapoptotic role (5). in mouse heart. Materials and Methods: Mice were divided Recombinant human erythropoietin (rHuEPO) induces a into five groups (n=7/group): A, control; B, rHuEpo-treated; proangiogenic phenotype in human endothelial cells, including C, (aFGF-treated); D, (VEGF-treated); E, (bFGF-treated). both early ( i.e. increase in cell proliferation and matrix The antibody mouse anti-human CD31 was used to evaluate metalloproteinase-2 production) and late (differentiation into the vessels present in histological preparations. Results: The vascular tubes) angiogenic events. In vivo , in the chick embryo results show a significant increase of the vessel number per CAM assay, the angiogenic activity of rHuEPO was similar to optical field in the rHuEpo-treated, the bFGF-treated and that exerted by basic fibroblast growth factor (bFGF), a well- the VEGF-treated animals compared to controls whereas known angiogenic cytokine and endothelial cells of the CAM aFGF did not show a ny significant angiogenic activity.
    [Show full text]